Concepedia

Mutagenic Impurity Control

Mutagenic Impurity Control is a specialized method within impurity control strategies that specifically identifies, assesses, and mitigates mutagenic impurities in pharmaceutical substances to prevent DNA damage and ensure patient safety.

11

Publications

286

Citations

65

Authors

23

Institutions

Publications per year

2017–2026

5

Parents

Publications

11

A Detailed Study of Sulfonate Ester Formation and Solvolysis Reaction Rates and Application toward Establishing Sulfonate Ester Control in Pharmaceutical Manufacturing Processes

Andrew Teasdale, Edward J. Delaney, Stephen C. Eyley et al. · Organic Process Research & Development · 2010 · 71 citations

, , +10

Mutagenicity of dichloroacetate, an ingredient of some formulations of pangamic acid (trade-named “vitamin B15”)

Victor Herbert, A. Gardner, N Colman · American Journal of Clinical Nutrition · 1980 · 35 citations

, , +11

Manufacturing Development and Genotoxic Impurity Control Strategy of the Hedgehog Pathway Inhibitor Vismodegib

Rémy Angelaud, Mark Reynolds, Cadapakam J. Venkatramani et al. · Organic Process Research & Development · 2016 · 31 citations

, , +17

Mutagenic Impurities: Precompetitive/Competitive Collaborative and Data Sharing Initiatives

David Elder, Angela White, James Harvey et al. · Organic Process Research & Development · 2015 · 23 citations

, , +15

Analytical control strategies for mutagenic impurities: Current challenges and future opportunities?

Andrew Teasdale, David Elder · TrAC Trends in Analytical Chemistry · 2017 · 23 citations

, , +17

1–5 of 11

Authors

65

  1. AT
    Andrew Teasdale

    AstraZeneca (United Kingdom), United Kingdom

    4 publications · 136 citations

    4

    h-index

  2. DE
    David Elder

    GlaxoSmithKline (United Kingdom), United Kingdom

    3 publications · 117 citations

    3

    h-index

  3. JE
    Jared Evans

    Johns Hopkins University Applied Physics Laboratory, United States

    1 publications · 19 citations

    1

    h-index

  4. EM
    Elizabeth M. Covey‐Crump

    AstraZeneca (United Kingdom), United Kingdom

    1 publications · 23 citations

    1

    h-index

  5. BR
    Baerbel Rueckert

    Siegfried (Switzerland), Switzerland

    1 publications · 31 citations

    1

    h-index

1–5 of 65

Institutions

23

  1. AstraZeneca (United Kingdom)

    Cambridge, United Kingdom

    3 h-index

    3 publications

    65 citations

  2. Merck & Co., Inc., Rahway, NJ, USA (United States)

    Rahway, United States

    2 h-index

    6 publications

    129 citations

  3. GlaxoSmithKline (United Kingdom)

    London, United Kingdom

    2 h-index

    4 publications

    88 citations

  4. Center for Environmental Health

    Oakland, United States

    1 h-index

    4 publications

    40 citations

  5. Takeda (United States)

    Deerfield, United States

    1 h-index

    1 publications

    19 citations

  6. Amgen (United States)

    Thousand Oaks, United States

    1 h-index

    1 publications

    19 citations

  7. University of Chinese Academy of Sciences

    Beijing, China

    1 h-index

    3 publications

    51 citations

  8. Gilead Sciences (United States)

    Foster City, United States

    1 h-index

    1 publications

    19 citations

1–8 of 23

Venues

  1. Organic Process Research & Development

    6 publications · 180 citations

    6

    h-index

  2. American Journal of Clinical Nutrition

    AJCN · 1 publications · 35 citations

    1

    h-index

  3. Cancer Letters

    1 publications · 10 citations

    1

    h-index

  4. TrAC Trends in Analytical Chemistry

    1 publications · 23 citations

    1

    h-index

  5. Research Journal of Chemistry and Environment

    1 publications · 21 citations

    1

    h-index

1–5